A study to test the safety and disease progression following YTB323 (rapcabtagene autoleucel) administration in participant with progressive Multiple Sclerosis (PMS)

Authors
Category Primary study
Registry of TrialsClinical Trials Information System
Year 2026
This article has no abstract
Epistemonikos ID: 6fdbc4289617a98b954c0b4ab7a4223b4b111d81
First added on: Jan 17, 2026